Search

Displaying results 6591 - 6600 of 8469 in total
  1. Drug

    TAK-733

    go.drugbank.com/drugs/DB12241
    Investigational

    TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.

  2. Drug

    Alagebrium

    go.drugbank.com/drugs/DB12497
    Investigational

    Alagebrium has been investigated for the treatment and prevention of Aging, Heart Failure, Physical Activity, Diabetic Nephropathy, and Cardiovascular Disease, among others.

  3. Drug

    Taladegib

    go.drugbank.com/drugs/DB12550
    Investigational

    Taladegib has been used in trials studying the treatment of Solid Tumor, COLON CANCER, BREAST CANCER, Advanced Cancer, and Rhabdomyosarcoma, among others.

  4. Drug

    Fluocinolone

    go.drugbank.com/drugs/DB12553
    Investigational

    Fluocinolone has been used in trials studying the treatment and prevention of Candida Infection, Oral Lichen Planus, Macular Degeneration, and Choroidal Neovascularization.

  5. Drug

    Emixustat

    go.drugbank.com/drugs/DB12608
    Investigational

    Emixustat has been used in trials studying the treatment of Geographic Atrophy, Age-Related Macular Degeneration, and Dry Age-related Macular Degeneration.

  6. Drug

    Ebselen

    go.drugbank.com/drugs/DB12610
    Investigational

    Ebselen has been investigated for the treatment and basic science of Meniere's Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus.

  7. Drug

    Samatasvir

    go.drugbank.com/drugs/DB12660
    Investigational

    Samatasvir has been used in trials studying the treatment of Hepatitis C, Chronic, Chronic Hepatitis C Virus, and Chronic Hepatitis C Infection.

  8. Drug

    Erythritol

    go.drugbank.com/drugs/DB04481
    Investigational

    It is twice as sweet as sucrose and can be used as a coronary vasodilator.

  9. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  10. Drug

    Buparlisib

    go.drugbank.com/drugs/DB11666
    Investigational

    Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.